Literature DB >> 26579561

Economic evaluation of schema therapy and clarification-oriented psychotherapy for personality disorders: a multicenter, randomized controlled trial.

Lotte L M Bamelis1, Arnoud Arntz, Pim Wetzelaer, Ryanne Verdoorn, Silvia M A A Evers.   

Abstract

PURPOSE: To compare from a societal perspective the cost-effectiveness and cost-utility of schema therapy, clarification-oriented psychotherapy, and treatment as usual for patients with avoidant, dependent, obsessive-compulsive, paranoid, histrionic, and/or narcissistic personality disorder.
METHOD: A multicenter, randomized controlled trial, single-blind parallel design, was conducted between May 2006 and December 2011 in 12 Dutch mental health institutes. Data from 320 patients (diagnosed according to DSM-IV criteria) randomly assigned to schema therapy (n = 145), treatment as usual (n = 134), or clarification-oriented psychotherapy (n = 41) were analyzed. Costs were repeatedly measured during 36 months by interview and patient registries. Primary outcome measures were proportion of recovered patients as measured with the Structured Clinical Interview for DSM-IV Axis II Personality Disorders for the cost-effectiveness analysis, and quality-adjusted life-years (QALYs) for the cost-utility analysis. Bootstrap replications in the cost-effectiveness and the cost-utility planes were used to estimate the probability that one treatment was more cost-effective than the other. Mixed gamma regression on net monetary benefit for different levels of willingness to pay for extra effects was used as sensitivity analysis. Additional sensitivity analyses were done to assess robustness of the results.
RESULTS: Due to higher clinical effects and lower costs, schema therapy was dominant over the other treatments in the cost-effectiveness analyses. Schema therapy has the probability of being the most cost-effective treatment (78% at €0 to 96% at €37,500 [$27,375] willingness to pay per extra recovery). Treatment as usual was more cost-effective than clarification-oriented psychotherapy due to lower costs. In the cost-utility analysis, schema therapy had a stable 75% probability of being cost-effective. Sensitivity analyses confirmed these findings.
CONCLUSIONS: The results support the cost-effectiveness of schema therapy but not of clarification-oriented psychotherapy. TRIAL REGISTRATION: Netherlands Trial Register NTR566. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26579561     DOI: 10.4088/JCP.14m09412

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective.

Authors:  Robbin H Ophuis; Joran Lokkerbol; Juanita A Haagsma; Mickaël Hiligsmann; Silvia M A A Evers; Suzanne Polinder
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

2.  Schematherapy in DID: treatment length and related studies on dissociative amnesia.

Authors:  R J C Huntjens; M M Rijkeboer; A Arntz
Journal:  Eur J Psychotraumatol       Date:  2020-01-09

3.  Towards optimal treatment selection for borderline personality disorder patients (BOOTS): a study protocol for a multicenter randomized clinical trial comparing schema therapy and dialectical behavior therapy.

Authors:  Carlijn J M Wibbelink; Arnoud Arntz; Raoul P P P Grasman; Roland Sinnaeve; Michiel Boog; Odile M C Bremer; Eliane C P Dek; Sevinç Göral Alkan; Chrissy James; Annemieke M Koppeschaar; Linda Kramer; Maria Ploegmakers; Arita Schaling; Faye I Smits; Jan H Kamphuis
Journal:  BMC Psychiatry       Date:  2022-02-05       Impact factor: 3.630

4.  Design of an RCT on cost-effectiveness of group schema therapy versus individual schema therapy for patients with Cluster-C personality disorder: the QUEST-CLC study protocol.

Authors:  Iuno Z Groot; Anne-Sophie S M Venhuizen; Nathan Bachrach; Simone Walhout; Bregje de Moor; Kasper Nikkels; Susanne Dalmeijer; Myrte Maarschalkerweerd; Joël R van Aalderen; Hinde de Lange; Renske Wichers; Agatha Ph Hollander; Silvia M A A Evers; Raoul P P P Grasman; Arnoud Arntz
Journal:  BMC Psychiatry       Date:  2022-10-08       Impact factor: 4.144

5.  Factorial Structure and Preliminary Validation of the Schema Mode Inventory for Eating Disorders (SMI-ED).

Authors:  Susan G Simpson; Giada Pietrabissa; Alessandro Rossi; Tahnee Seychell; Gian Mauro Manzoni; Calum Munro; Julian B Nesci; Gianluca Castelnuovo
Journal:  Front Psychol       Date:  2018-04-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.